Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Genotyping firm DxS to sell AstraZeneca technology:

This article was originally published in Clinica

Executive Summary

Manchester, UK-based DxS, which provides genotyping services based on proprietary PCR-based technology, and BTG, an international group that specialises in developing technologies for licensing, are to commercialise a system owned by AstraZeneca. Called ARMS (Amplification Refractory Mutation System), it can be used to detect gene mutations and single nucleotide polymorphisms, and will be pitched to the diagnostic and research markets. For instance, it could be used to predict which patients will respond well to a medicine.






Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts